AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid Carcinoma
February 2, 2024 updated by: Yunfang Yu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid Carcinoma: A Retrospective Study
This study involved a comprehensive analysis of 256 PTC patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH) and 499 patients from The Cancer Genome Atlas.
DNA-based next-generation sequencing (NGS) and single-cell RNA sequencing (scRNA-seq) were employed to capture genetic alterations and TME heterogeneity.
A deep learning multimodal model was developed by incorporating matched histopathology slide images, genomic, transcriptomic, immune cells data to predict LNM and disease-free survival (DFS).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
256
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Herui Yao, PhD
- Phone Number: +8613500018020
- Email: yaoherui@mail.sysu.edu.cn
-
Contact:
- Yufang Yu
- Phone Number: +8613660238987
- Email: yuyf9@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Description
Inclusion Criteria:
≥ 18 years of age Diagnosis of Papillary thyroid carcinoma at least one months before trial Willing to return for required follow-up (posttest) visits
Exclusion Criteria:
The patient requires valve or other likely surgery The patient is unable to carry out any physical activity without discomfort The patient had thyroid ache within three months prior to enrollment The patient refuses to give informed consent The patient is a candidate for coronary bypass surgery or something similar
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
TCGA
|
|
SYSMH
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lymph node metastasis
Time Frame: 2021.10.1
|
Lymph node metastasis is frequently influenced by a myriad of factors, and tumor heterogeneity stands out as a significant contributing element.
|
2021.10.1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-free survival
Time Frame: 2021.10.1
|
Disease-free survival is defined as the time from randomization to the first occurrence of a relapse, progression, or death from any cause, commonly used in clinical trials of adjuvant therapy after curative surgery or radiation therapy.
It is also used as a primary endpoint in studies of neoadjuvant therapy and a useful endpoint for evaluating the efficacy of treatments that aim to prevent cancer recurrence research
|
2021.10.1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
September 20, 2024
Study Completion (Estimated)
January 20, 2025
Study Registration Dates
First Submitted
January 16, 2024
First Submitted That Met QC Criteria
February 2, 2024
First Posted (Estimated)
February 5, 2024
Study Record Updates
Last Update Posted (Estimated)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Neoplastic Processes
- Adenocarcinoma, Papillary
- Carcinoma
- Neoplasm Metastasis
- Thyroid Diseases
- Lymphatic Metastasis
- Thyroid Neoplasms
- Thyroid Cancer, Papillary
Other Study ID Numbers
- SYSEC-KY-KS-2021-259
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.